Royalty Report: Drugs, Cancer, Disease – Collection: 301547

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Diagnostic
  • cardiac
  • Dermatology
  • Pharmaceuticals
  • Nutraceutical
  • Personal Care Products
  • Respiratory
  • Tissue
  • Internet
  • Software
  • Game
  • Online Games-MMOG
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 301547

License Grant
Licensor granted Polish Sublicensee an exclusive sublicense, even as to Licensor, for the patent rights Licensor licensed pursuant to the HPI License within the following countries Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Bulgaria, Serbia, Macedonia, Albania, Armenia, Azerbaijan, Georgia, Montenegro, Bosnia, Croatia, Slovenia, Slovakia, Czech Republic, Hungary, Chechnya, Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Greece, Austria, and Russia. The sublicense agreement provides that Sublicensee must use commercially reasonable development efforts to attempt to develop and commercialize licensed products in the above mentioned territories.

Under the HPI License Licensor obtained the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer anywhere in the world

License Property
Berubicin is an anthracycline, which is a class of drugs that are among the most powerful chemotherapy drugs known and as a class are effective against more types of cancer than any other class of chemotherapeutic agents.
Field of Use
The chemical compound is commonly known as Berubicin and used in the treatment of glioblastoma.  Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain.

IPSCIO Record ID: 218779

License Grant
The Licensor hereby grants to Licensee and to the Licensee of Spain, an exclusive right and license throughout the Territory, for Europe and for the U.S., sublicensable through multiple tiers and assignable, to practice under and otherwise use the Licensor Intellectual Property to research, Develop, Commercialize, make, have made, and otherwise exploit the Licensed Products for topical treatment of actinic keratosis, in the Field in the Territory.  Field means the treatment or prevention of any skin disorder or skin disease in humans, including any skin cancer treated by dermatologists.
License Property
The Licensor is developing a topical formulation of the Compound for the treatment of actinic keratosis – KX2-391.
Field of Use
The Licensees have experience in the development, marketing, promotion and sale of pharmaceutical products and will further develop and commercialize KX2-391 for the treatment of actinic keratosis and other skin conditions.

IPSCIO Record ID: 257476

License Grant
For Licensors intellectual property, Licensor grants the Licensee of China an exclusive right and license under Licensors Intellectual Property applicable to the Licensed Product to develop, manufacture, market, sell, use, offer for sale and import the Licensed Product in the Territory during the term of this Agreement.

Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.

License Property
Licensor has intellectual property relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Irinotecan is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Irinotecan is used to treat cancers of the colon and rectum. It is usually given with other cancer medicines in a combination chemotherapy.

Field of Use
Irinotecan is used as a chemotherapy drug.

IPSCIO Record ID: 257586

License Grant
This amendment reflects the new parent of the Licensor, re-assignment of a sublicense, territories and royalties.

Licensor of Bermuda and its Parent, the Licensee, desire to amend the Agreement to transfer back to Licensor the right to develop and commercialize the Licensed Product in certain countries in Asia.   The original agreement was exclusive.

License Property
The Licensor has rights relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Field of Use
Liposomal irinotecan is used in chemotherapy.

IPSCIO Record ID: 259855

License Grant
Licensor grants the Sublicensee, of Poland, an exclusive sublicense even as to Licensor under the Sublicensed Subject Matter to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell Sublicensed Products within the Sublicensed Territories for use within the Sublicensed Field.

Licensor has obtained licenses to research, develop, make, have made, use, offer to sell, sell, export and/or import and commercialize Licensed Products within the Licensed Territory for use within the Licensed Field under Patent Rights.

License Property
The grant is for certain intellectual property rights, including rights to Annamycin, Licensors WP1122 portfolio, and WP1066 portfolio.
Field of Use
The Sublicensed Field means the field of pharmaceutical drug products for the treatment of any illness, disease, or symptom in humans.

Licensor is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. The Licensor's clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.

IPSCIO Record ID: 257617

License Grant
This amendment addresses new parent for Licensor, territories and royalties.

With the original agreement, Licensors intellectual property, Licensor grants the Licensee of China an exclusive right and license under Licensors Intellectual Property applicable to the Licensed Product to develop, manufacture, market, sell, use, offer for sale and import the Licensed Product in the Territory during the term of this Agreement.

Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.

License Property
Licensor has intellectual property relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Field of Use
Irinotecan is used as a chemotherapy drug.
MM-398 is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. MM-398 recently achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer.

IPSCIO Record ID: 4374

License Grant
Licensor hereby grants to Licensee, a UK Corporation, an exclusive sublicensable, transferrable license under the Licensor's Patents, Know-How,  Inventions and Licensor’s rights in the Joint Inventions and/or Joint Invention Patents to Commercialize the Licensed Product in the Field in the Territory.
License Property
Licensor invented a proprietary compound known as Telavancin (VIBATIV®) for the treatment of serious Gram-positive bacterial infections in humans.

VIBATIV®  is for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable.

VIBATIV® is a bactericidal, once-daily injectable lipoglycopeptide antibiotic approved in the U.S. and Canada for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

Field of Use
Field means veterinary or human pharmaceutical use of the Licensed Product.

IPSCIO Record ID: 3446

License Grant
The Licensor grants to the Spanish Licensee, an affiliated party, the exclusive right and license to enjoy, commercialize and exploit, use and sell the Products throughout the Territory.
License Property
The Licensor has developed or is in the process of developing the products s Food Supplements, Hair and Dermatological Products, Energy Drinks and Chewing Gum (the Products);

Products

1.
Lamiridosin

2.
Lamiricream (2)

3.
Lamirigel (3)

4.
Lamirishampoo

5.
Lamiriconditioner

6.
Lamirihairtonic

7.
KTKin

8.
KTK Chewing Gum

9.
KTKids Children Chewing Gum.

Patent Application Number

1. US Patent Application #20080319042 Compositions and Methods of Treatment of Liver Disease
2. PCT/US2008/001912 Compositions and Methods of Treatment of Liver Disease.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 266853

License Grant
Licensor grants the German Licensee a non-transferable, exclusive license, with the right to sublicense, under the Licensed Product Patents to develop, commercialize, market, sell and distribute, but not manufacture, the Licensed Product in the Field in the Territory.

Licensor grants a non~exclusive, non•transferable license, with the right to sublicense, to use the Licensors Mark solely within the Territory and solely in connection with the sale of the Licensed Product in the Field.

License Property
The Licensed Product shall mean any pharmaceutical form, dosage, strength, or formulation of TheraCLEC-Total purchased from Licensor.

TheraCLEC-Total shall mean commercial formulations of that product currently known as TheraCLEC-Total consisting of the enzymes, lipase, amylase and protease.

Field of Use
The Field shall mean the treatment of symptoms (e.g. malabsorption or pain) directly caused by exocrine pancreatic insufficiency.  TheraCLEC is a novel orally delivered enzyme replacement therapy that is intended to replace digestive enzymes in patients suffering from pancreatic insufficiency.

IPSCIO Record ID: 257477

License Grant
The Licensor of China assigns and transfers to the SubLicensee of Bermuda all of Licensors rights and obligations under the License Agreement.

Licensor grants
—  an exclusive right and license under the Licensors Licensed Technology and rights to the Joint Technology, to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, have sold, import and export the Licensed Compound and the Licensed Product in the Field outside the Licensor Territory; provided that Licensor reserves the right to conduct Development activities outside the Licensor Territory solely to support the Development and Commercialization of Licensed Compound and Licensed Products inside the Licensor Territory, and manufacture Licensed Compound and Licensed Products outside the Licensor Territory solely for use and distribution within the Licensor Territory; and,

— a non-exclusive right and license in the Field in the Licensor Territory under the Licensor Licensed Technology and rights to the Joint Technology, to the extent necessary for SubLicensee to perform its obligations under the Development Plan, and to Develop and manufacture the Licensed Compound and the Licensed Product in the Licensor Territory solely in support of Development and Commercialization of the Licensed Compound and the Licensed Product outside the Licensor Territory.

Previously, the development and commercialization rights to MM-398 in Europe and Asia had been licensed to Licensor. Sublicensee held the rights to the product in North America and all other territories around the world. Through this agreement, the worldwide rights to MM-398 have been reunited, with SubLicensee now having the right to develop and commercialize MM-398 in all territories of the world with the exception of Taiwan, where Licensor will retain its rights to develop and commercialize MM398.

License Property
MM-398 is a highly stable nanoliposomal formulation of irinotecan.  MM-398, or irinotecan, is used with chemotherapy treatments.

The property of the original agreement which is being reassigned with this agreement is
Intellectual property relating to liposomal irinotecan;  Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof;  and,  patents for Liposomes Useful for Drug Delivery.

Field of Use
Field means all human and veterinary fields of use, including therapeutic, prophylactic, palliative and diagnostic uses in all possible indications.   MM-398, or irinotecan, is used with chemotherapy treatments.

IPSCIO Record ID: 203357

License Grant
Licensor grants to the Licensee of Denmark an exclusive license under the Licensor Technology to use, develop, market, advertise, promote, distribute, offer for sale, sell, import, package and label, but not to make or have made, the Product in the Territory for use in the Field, with a right to sublicense, which   Licensee shall have the right to grant, only with Licensors prior written consent.  The Parties shall conduct activities using the Licensor Technology to develop the Product for use in the Field in the Territory.
License Property
The licensed property is related to the Product, including Licensors proprietary drug delivery system based on porous microparticles and which is under the Control of Licensor.

The Product is Al-700, a medical product under development by Licensor, initially as an ultrasound contrast agent for use in the evaluation of coronary disease, currently comprised of a sterile, lyophilized powder in glass vials for individual usage, in the form ultimately approved for sale in the Territory and as further described in the Specifications, and all formulations, line extensions and package configurations.

AI-700 is an ultrasound contrast agent for use in the evaluation of coronary artery disease. AI-700 is being developed as a cost-effective and convenient alternative to current nuclear-imaging methods.

A competitive product means any ultrasound contrast agent and any radioisotope product which could be substituted in full or in part for the Product for use in the Field in the Territory.

Field of Use
The Field means the evaluation of coronary heart disease and other medical applications of the Product.

IPSCIO Record ID: 238361

License Grant
Licensor hereby grants to Licensee an exclusive license, even as to Licensor, under the Patent Rights, to research, develop, make, have made, use, offer to sell, sell, export and/or import and commercialize Licensed Products within the Licensed Territory for use within the Licensed Field. For purposes of clarity Licensee shall have the right, but not the obligation, to conduct research regarding the Patent Rights. For the avoidance of doubt and except as to the Patent Rights and rights to Technology granted, nothing in this Agreement shall serve to grant Licensee any right, title or interest to any other intellectual property right owned or controlled by Licensor. Moreover, Licensee agrees and acknowledges that nothing in this Agreement shall preclude Licensor from engaging in future research, development, production, distribution, sale or commercialization of any product or service in the Licensed Field, or which may compete with a Licensed Product, provided such product or service are not covered by the Patent Right licensed herein.
License Property
The technology and patents are for the chemical compound commonly known as Berubicin.  Berubicin is an anthracycline, which is a class of drugs that are among the most powerful chemotherapy drugs known and as a class are effective against more types of cancer than any other class of chemotherapeutic agents.

Berubicin is a novel therapy for the treatment of glioblastoma. Berubicin is one of the first anthracyclines (the most potent class of cancer drugs) to cross over the blood brain barrier and kill tumor cells in humans.

Glioblastoma is a type of astrocytoma, a cancer that forms from star-shaped cells in the brain called astrocytes. In adults, this cancer usually starts in the cerebrum, the largest part of your brain. Glioblastoma tumors make their own blood supply, which helps them grow

Field of Use
Licensed Field means the use of Licensed Product for the treatment of cancer through any type of administration, whether now known or yet to be developed.

IPSCIO Record ID: 158673

License Grant
Licensor hereby grants to Licensee of Switzerland the exclusive right to utilize such rights as are held by Licensor to develop, use, promote, market and sell, directly or indirectly, each Product in the Territory pursuant to the Know-How, Patents and Improvements.
License Property
The Patent Rights are for Chystalline amifostine compositions and methids for the preparation and use of same.  The Trademark means the trademark Ethyol(R) or the trademark NeuTrexin(R).

Licensor has rights relating to a pharmaceutical product known as Ethyol(R) (amifostine) which is being developed by Licensor for use in reducing toxicities of chemotherapeutic cancer treatments and as a radioprotective agent and Licensor has rights relating to a pharmaceutical product known as NeuTrexin(R) (trimetrexate glucuronate for injection).

Amifostine is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents.

Field of Use
The product are of use in treating Pneumocystis carinii pneumonia ('PCP') and as an anti-cancer agent.

IPSCIO Record ID: 203519

License Grant
The Parties previously entered a Collaboration Agreement provided Licensor the opportunity to participate in the development and commercialization of INTEGRILIN(R) (eptifibatide) Injection (INTEGRILIN).

The Parties wish to terminate Licensors role in the commercialization and manufacturing of INTEGRILIN in and for the Transferring Territory, and to have Licensors existing regulatory approvals and authorizations, contractual rights and responsibilities transferred in an appropriate manner to a new commercial licensee that this Licensee will identify.

This agreement, terminates certain License rights and modifies other certain license rights terms.  For the Modification of IP Licenses Granted to Licensee
– the exclusive licenses under the Licensor Patents granted in the Collaboration Agreement shall be exclusive even as to Licensor solely with respect to Commercializing INTEGRILIN Products in the relevant country or countries or in the Transferring Territory, as applicable;
– the non-exclusive licenses under the Licensor Patents granted in the Collaboration Agreement with respect to the Manufacture of INTEGRILIN Products shall be exclusive, except as to Licensor and its Affiliates, with respect to the Manufacture of INTEGRILIN Products for distribution, use and/or sale in the relevant country or countries or in the Transferring Territory,
– the non-exclusive licenses to use the Licensor Know-how granted in the Collaboration Agreement shall be exclusive even as to Licensor solely with respect to Commercializing INTEGRILIN
– the non-exclusive licenses to use the Licensor Know-how granted in the Collaboration Agreement with respect to Manufacturing INTEGRILIN Products shall be exclusive, except as to Licensor solely with respect to Manufacturing INTEGRILIN Products in or for the relevant country or countries or in or for the Transferring Territory.

For Certain Copyrights and Trademarks, Licensor grants to Licensee and the New Commercial Licensee an exclusive, perpetual, sublicensable license under Licensors copyrights in all Marketing Materials solely for use in Commercializing INTEGRILIN Products in the Transferring Territory.

License Property
INTEGRILIN(R) (eptifibatide) Injection (INTEGRILIN), is a small peptide pharmaceutical.  INTEGRILIN prevents blood clots or heart attack in people with severe chest pain and in patients undergoing angioplasty.

The Trademark means all registrations, applications for registration and other rights in and to the INTEGRILIN mark and the APEREXIN back-up mark for the Development, Manufacture and Commercialization of INTEGRILIN Products in or for the Transferring Territory.

The New Commercial Agreement means a definitive agreement between Licensee and a Pharmaceutical Company under which such Pharmaceutical Company is granted a license to INTEGRILIN Products and assumes primary responsibility for the Development and Commercialization of the INTEGRILIN Products in and for the Transferring Territory, and the Manufacture of the INTEGRILIN Products for Development and Commercialization in the Transferring Territory.

Field of Use
The Field means the treatment, prevention and/or control of cardiovascular diseases and conditions in humans.

IPSCIO Record ID: 152770

License Grant
Licensor grants to the Japanese Licensee a perpetual, exclusive license, with the right to grant sublicenses, under Licensors Patents and know-how to make, have made, use, sell and have sold product and finished product within the field and territories.
License Property
Patents and know-how are relating to products directed against Macrophage Migration Inhibitory Factor (MIF), and the use of such products for the potential palliation, evaluation, diagnosis and treatment and/or prophylaxis of human disease states which are caused or exacerbated by MIF.  The products are those in which composition of matter contains antibodies against MIF.

Macrophage migration inhibitory factor (MIF or MMIF), also known as glycosylation-inhibiting factor (GIF), L-dopachrome isomerase, or phenylpyruvate tautomerase is a protein that in humans is encoded by the MIF gene.

Field of Use
The field shall mean use of the products for in vivo therapy of human disease and in vivo diagnosis and in vitro diagnosis and evaluation of human tissue or fluid.

IPSCIO Record ID: 372549

License Grant
Licensor grants the following rights to Licensee of Luxembourg
—  an exclusive, sublicensable license under the Licensor Know-How and the Patent Rights, and under s interest in any Licensors Joint Know-How and Joint Patent Rights, to develop, register, use, have used, market, sell, have sold, distribute, have distributed, import, have imported, export and have exported or otherwise Commercialize the Product in the Field solely in the Territory;
—  Licensor grants an exclusive license, sublicensable license under the Licensor Know-How and Patent Rights, and under Licensors interest in any Joint Know-How and Joint Patent Rights, to package or have packaged, inside and outside the Territory;
—  Licensor grants to an exclusive, sublicensable license under the Licensor Know-How and Licensor Patent Rights, and under Licensors interest in any Joint Know-How and Joint Patent Rights, to conduct those Phase IV studies in respect of the Licensee product that are to be conducted, inside the Territory, solely for the purpose of Commercializing the Product in the Field in the Territory.

Regarding the Trademarks, Ownership of all Trademarks in the Territory currently owned by Licensor, which consist only of the Ranexa® and Latixa® marks as registered in the European Union as of the Effective Date, shall be transferred within thirty days after the Effective Date to Licensee, and the Parties agree to enter into customary assignment documentation in order to effectuate such transfer. The Parties intend that ownership of these marks and all other Trademarks, if any, under this Agreement shall revert to Licensor on termination.

License Property
Compound shall mean the racemic form of the chemical substance having the chemical name (!)N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine acetamide (also known by the generic name of ranolazine) including salts thereof.

The trademarks shall mean the Ranexa® and Latixa® trademarks, and any other trademark(s) which the Parties may mutually agree from time to time should be used instead of Ranexa® in any country in the Territory.

Field of Use
RANEXA is a prescription medicine used to treat angina that keeps coming back
(chronic angina).  RANEXA may be used with other medicines that are used for heart problems and blood pressure control.

Angina, also known as angina pectoris, is chest pain or pressure, usually due to insufficient blood flow to the heart muscle (myocardium).

The Initial Indication shall mean any use as add-on therapy for the symptomatic  treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies such as beta blockers and/or calcium antagonists.

IPSCIO Record ID: 635

License Grant
The Russian Licensee and Korean Licensor entered into a this non-transferable, exclusive and royalty-bearing License and distribution agreement within the territory of shall mean the territory of the Former Soviet Republics  Armenia, Azerbaijan, Belorussia, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.
License Property
Licensor has developed and owns all rights in computer programs of online game Requiem Online.  Requiem is a massively multiplayer online role-playing game.

Unless explicitly approved in writing by the Licensor, the Licensee shall have no right to sublicense.

Field of Use
This Exclusive Requiem Online License and Distribution Agreement is with respect to Intellectual Property rights which shall mean all patents, designs, utility models, copyrights, know-how, trade secrets, trademarks, service mark, trade dress and any other intellectual property rights in or related to the Game or Technical Information.  Licensee shall provide Game services only by way of the PC on-line method (excluding mobile access) using the Servers.

IPSCIO Record ID: 67167

License Grant
The Licensor grants the Licensee a royalty-bearing, exclusive license under the Licensed Subject Matter to manufacture, have manufactured, use, import, offer to sell and/or sell Licensed Products within the Territory for use within the fields of human therapeutics for  topical anticancer drugs. The Licensee may grant sublicenses.
License Property
The license relates to the development of topical anticancer drugs.
Field of Use
Licensed field means the fields of human therapeutics.

IPSCIO Record ID: 362680

License Grant
The Licensee is party to an exclusive license with Licensor for the development and commercialization of Dexmedetomidine for use in the treatment of pain in humans in any dosage form for transdermal, transmucosal (including sublingual and intranasal), topical, enteral or pulmonary (inhalational) delivery, but specifically excluding delivery vehicles for administration by injection or infusion, worldwide, except for Europe, Turkey and the CIS (currently includes Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan), referred to herein as the Territory.
License Property
Dexmedetomidine means the compound known as “dexmedetomidine” or 4-((1S-1-(2,3-Dimethylphenyl)ethyl)-1H-imidazole including hydrates, stereoisomers, salts, and mixtures thereof.

Dex (dexmedetomidine) is a selective alpha-2 adrenergic agonist that has demonstrated sedative, analgesic and anxiolytic properties. Dex has an extensive commercial history of safe injectable use.

Field of Use
Field of use is for the treatment of pain in humans.

IPSCIO Record ID: 26186

License Grant
The Licensor grants to the German Licensee an exclusive royalty bearing license and, as the case may be, an exclusive royalty bearing Sublicense under the Patents, the Trademarks, the Product Know-How and the Product Data (all as defined below and collectively referred to as the licensed assets) to the extent necessary to obtain marketing authorisations for, and to manufacture,  have manufactured, to market, have marketed, to distribute, have distributed, and to sell and have sold the Product in the field of dermatology in the Territory.
License Property
The Product is Food and Drug Administration approved, New Drug Application 50/805 covering the marketing and sale of a 40mg controlled release doxycycline monohydrate capsule conforming to the specifications described in such application.

The Patents relate to Oracea, the Company’s dermatology product for the systemic treatment of rosacea.  Methods of treating acne.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.